clinical trial · NCT06682780
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Advanced Solid TumorLM-2417DocetaxelToripalimab/TirelizumabCarboplatinNiraparibLenvatinib
brief summary
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.
started
Sep 17, 2025
primary completion
Dec 25, 2028
completion
Dec 1, 2029
last updated
Sep 25, 2025
official title
An Open-label, Dose-escalation, and Dose-expansion Phase I/II Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of LM-2417 for Injection Alone or in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol